Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biorestorative Therapies Inc (BRTX)

Biorestorative Therapies Inc (BRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,884
  • Shares Outstanding, K 9,046
  • Annual Sales, $ 400 K
  • Annual Income, $ -8,980 K
  • EBIT $ -15 M
  • EBITDA $ -14 M
  • 60-Month Beta 0.47
  • Price/Sales 4.93
  • Price/Cash Flow N/A
  • Price/Book 0.78
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.44
  • Most Recent Earnings $-0.38 on 11/12/25
  • Next Earnings Date 03/26/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -85.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1900 +14.42%
on 02/23/26
1.1300 -80.76%
on 02/06/26
-0.8126 (-78.89%)
since 02/04/26
3-Month
0.1900 +14.42%
on 02/23/26
1.2799 -83.01%
on 01/05/26
-0.8926 (-80.41%)
since 12/04/25
52-Week
0.1900 +14.42%
on 02/23/26
2.1000 -89.65%
on 03/25/25
-1.2126 (-84.80%)
since 03/04/25

Most Recent Stories

More News
BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy

Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation continues...

BRTX : 0.2174 (+4.37%)
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks.  BioRestorative believes its cell-based therapeutic...

BRTX : 0.2174 (+4.37%)
BioRestorative Announces Closing of $5.0 Million Public Offering

MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator...

BRTX : 0.2174 (+4.37%)
BioRestorative Announces Pricing of $5.0 Million Public Offering

MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator...

BRTX : 0.2174 (+4.37%)
BioRestorative Announces Positive Outcome from Type B Meeting with FDA

BioRestorative completed a Type B meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential accelerated Biologics License Application (“BLA”) approval pathway for the Fast-Track-Designated...

BRTX : 0.2174 (+4.37%)
BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease

Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc disease The study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or...

BRTX : 0.2174 (+4.37%)
BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease

MELVILLE, N.Y., Nov. 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused...

BRTX : 0.2174 (+4.37%)
BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update

MELVILLE, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused...

BRTX : 0.2174 (+4.37%)
BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused...

BRTX : 0.2174 (+4.37%)
BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused...

BRTX : 0.2174 (+4.37%)

Business Summary

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The company's core programs consist of Disc/Spine Program and Metabolic Program. Disc/Spine Program consists of cell therapy candidate, brtxDISC(TM)...

See More

Key Turning Points

3rd Resistance Point 0.2452
2nd Resistance Point 0.2326
1st Resistance Point 0.2204
Last Price 0.2174
1st Support Level 0.1956
2nd Support Level 0.1830
3rd Support Level 0.1708

See More

52-Week High 2.1000
Fibonacci 61.8% 1.3704
Fibonacci 50% 1.1450
Fibonacci 38.2% 0.9196
Last Price 0.2174
52-Week Low 0.1900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar